ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

FFWD Fastforward Innovations Limited

8.25
0.00 (0.00%)
28 Mar 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Fastforward Innovations Limited LSE:FFWD London Ordinary Share GG00BRK9BQ81 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 8.25 8.00 8.50 0.00 00:00:00
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
0 0 N/A 0

FastForward Innovations Limited Investee Company Update: EMMAC Life Sciences (9913P)

16/10/2019 7:00am

UK Regulatory


Fastforward Innovations (LSE:FFWD)
Historical Stock Chart


From Mar 2019 to Mar 2024

Click Here for more Fastforward Innovations Charts.

TIDMFFWD

RNS Number : 9913P

FastForward Innovations Limited

16 October 2019

16 October 2019

FastForward Innovations Ltd / AIM: FFWD / Sector: Closed End Investments

FastForward Innovations Ltd

("FastForward", "FFWD" or the "Company")

Investee Company Update: EMMAC raised GBP15 million through issue of convertible loan notes

FastForward Innovations Ltd, the AIM quoted company focusing on making investments in fast growing and industry leading businesses, notes the following announcement released on 16 October 2019 concerning investee company EMMAC Life Sciences Limited ("EMMAC"). FastForward has a 2.3% interest in the issued stock of EMMAC.

The convertible note is convertible at a 20% discount to the price of the next eligible fundraise by EMMAC capped at GBP0.50 per share. At a conversion price of GBP0.50 per share, EMMAC has an implied value of greater than GBP150 million. Following FFWD's investment in March 2019 the implied value of EMMAC was GBP77 million (post-investment).

The announcement is set out below without material changes or adjustments.

EMMAC Life Sciences Group

('EMMAC' or the 'Group')

GBP15 million raised via successful issue of convertible notes

16 October 2019, London. EMMAC Life Sciences Group, Europe's leading independent cannabis company, is pleased to announce that it has raised GBP15 million via an issue of Convertible Loan Notes (the 'CLN Issue'). The CLN Issue saw funds coming from a range of new and existing private and institutional investors based in Europe, North America, Asia and Australia. The proceeds from the Placing will be used by EMMAC to further establish its position as Europe's leading independent cannabis company.

In addition to the initial seed capital of GBP2 million, EMMAC raised a further GBP6 million in January 2019, followed by GBP11 million in March 2019 and with this latest CLN Issue, it provides a combined total of GBP34 million of funds raised by the Group in the last twelve months. The CLN Issue provides for notes to be converted to ordinary shares at a price of up to GBP0.50 per share giving EMMAC an implied value in excess of GBP150 million.

Antonio Costanzo, CEO of EMMAC, said: "We are delighted to have seen such significant demand for our latest fundraising, with almost two thirds of the funds coming from new institutional investors. The strong reception that we have received has been extremely encouraging and bodes well for the future of EMMAC. We are not aware of any other UK private medical cannabis company that has raised this quantum of funds to date and we believe that it is testament to EMMAC's strategy, strength of management team, and our market leading position. I would personally like to welcome all of our new investors as well as thank our existing shareholders for their continued support.

"2019 has been an extremely busy year for EMMAC as we have executed our strategy to build a strong position in Europe in the medical cannabis and wellness markets, with operations in eight countries. We now have an established presence in all aspects of the cannabis supply chain and are well placed to meet the rapidly growing demands of the market, driven by regulatory change and consumer demand."

About EMMAC

EMMAC Life Sciences Group is Europe's leading independent cannabis company, bringing together pioneering science and research with cutting-edge cultivation, extraction and production. With a unique supply and distribution network throughout Europe, EMMAC's vision is to bring the life-enhancing potential of cannabis to the people who need it.

Contact:

For scientific enquiries please contact research@emmac.com

For general enquiries please contact info@emmac.com or visit www.emmac.com

*** ENDS***

Miscellaneous

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014.

Cautionary Statement

The AIM Market of London Stock Exchange plc does not accept responsibility for the adequacy or accuracy of this release. No stock exchange, securities commission or other regulatory authority has approved or disapproved the information contained herein. All statements, other than statements of historical fact, in this news release are forward-looking statements that involve various risks and uncertainties, including, without limitation, statements regarding potential values, the future plans and objectives of FastForward Innovations Ltd. There can be no assurance that such statements will prove to be accurate, achievable or recognizable in the near term.

Actual results and future events could differ materially from those anticipated in such statements. These and all subsequent written and oral forward-looking statements are based on the estimates and opinions of management on the dates they are made and are expressly qualified in their entirety by this notice. FastForward Innovations assumes no obligation to update forward-looking statements should circumstances or management's estimates or opinions change.

ENDS

For further information on the Company please visit www.fstfwd.co or contact:

 
 Ed McDermott / Lance    FastForward Innovations   Email: info@fstfwd.co 
  de Jersey               Ltd 
 James Biddle / Roland   Beaumont Cornish               Tel: +44 (0) 207 
  Cornish                 Limited,                              628 3396 
                          Nomad 
                        ------------------------  ---------------------- 
 Graham Dickson          Optiva Securities              Tel: +44 (0) 203 
                          Limited,                              411 1881 
                          Broker 
                        ------------------------  ---------------------- 
 Megan Dennison          St Brides Partners              Tel: +44 (0)207 
                          Ltd,                                  236 1177 
                          Financial PR 
                        ------------------------  ---------------------- 
 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

MSCFFIFMIFUSEDS

(END) Dow Jones Newswires

October 16, 2019 02:00 ET (06:00 GMT)

1 Year Fastforward Innovations Chart

1 Year Fastforward Innovations Chart

1 Month Fastforward Innovations Chart

1 Month Fastforward Innovations Chart

Your Recent History

Delayed Upgrade Clock